Efficacy of laser surgery versus radiotherapy for treatment of glottic carcinoma: a systematic review and meta-analysis

Ding, Yongxia; Wang, Binquan

doi:10.1007/s10103-018-2695-2

Cited by 12 publications

(11 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thanks to the numerous series now present in the international literature, CO 2 TOLMS is currently considered a valid treatment option for laryngeal cancer even in the absence of highquality randomized clinical trials comparing it with alternatives (ie, RT and OPHL). In particular, several systematic reviews and meta-analyses have confirmed its noninferiority as compared with RT for EIGSCC, in terms of oncologic and functional outcomes, [14][15][16][17][18][19][20] with a trend toward better results in CO 2 TOLMS. However, because of the relatively recent widespread use of CO 2 TOLMS, there is a paucity of information on long-term oncologic and OP results.…”

Section: Discussionmentioning

confidence: 98%

Long‐term Oncologic Outcomes of 1188 Tis‐T2 Glottic Cancers Treated by Transoral Laser Microsurgery

Piazza¹,

Paderno²,

Bon³

et al. 2021

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Objective To evaluate long-term disease-specific survival (DSS) and organ preservation (OP) rates in patients affected by Tis-T2 glottic squamous cell carcinoma (SCC) treated by carbon dioxide transoral laser microsurgery (CO2 TOLMS). Study Design Single-center retrospective cohort study. Setting Tertiary academic hospital. Methods The study included patients treated by CO2 TOLMS for Tis-T2 glottic SCC at the Department of Otorhinolaryngology–Head and Neck Surgery of the University of Brescia, Italy, from 1988 to 2018. The male:female ratio was 11.2:1, and the mean age was 64 years (range, 31-95). T categories were distributed as follows: 124 (10%) Tis, 646 (54%) T1a, 172 (15%) T1b, and 246 (21%) T2. Results Ten- and 20-year DSS rates were 97.6% and 96.3%, respectively, and 10- and 20-year OP rates were 94.7% and 93%. During the follow-up, 91% of patients were treated by CO2 TOLMS alone, while the remaining needed adjunctive treatments. Assessing the impact of multiple sessions of CO2 TOLMS, DSS showed no significant difference in terms of patients treated by 1, 2, or >2 procedures. Conversely, patients treated by >2 sessions of CO2 TOLMS showed a significantly worse OP rate. Conclusions Our series validates CO2 TOLMS as a long-term treatment strategy for early glottic SCC. Salvage CO2 TOLMS provided optimal results in terms of DSS and OP in patients with recurrence after previous transoral surgery.

show abstract

Section: Discussionmentioning

confidence: 98%

Long‐term Oncologic Outcomes of 1188 Tis‐T2 Glottic Cancers Treated by Transoral Laser Microsurgery

Piazza¹,

Paderno²,

Bon³

et al. 2021

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

“…T1 glottic laryngeal squamous cell carcinoma (LSCC) can be treated either with trans-oral laser surgery or with radiotherapy. The prognosis is excellent regardless of the treatment method [1][2][3][4][5][6][7][8]. In Finland, LSCC is mainly treated in university hospitals.…”

Section: Introductionmentioning

confidence: 99%

T1 glottic laryngeal cancer: the role of routine follow-up visits in detecting local recurrence

Pakkanen

Ilmarinen

Halme

et al. 2021

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Purpose We assessed the treatment outcome and the benefits of routine follow-up visits in T1 glottic laryngeal squamous cell carcinoma (LSCC). Methods Medical records of patients diagnosed with stage T1 glottic LSCC (N = 303) in five Finnish university hospitals between 2003 and 2015 were reviewed. Moreover, data from the Finnish Cancer Registry and the Population Register Center were collected. Results Of all 38 recurrences, 26 (68%) were detected during a routine follow-up visit, and over half (21 of 38, 55%) presented without new symptoms. Primary treatment method (surgery vs. radiotherapy) was not connected with 5-year disease-specific survival (DSS) or laryngeal preservation rate. Conclusion The majority of recurrences were detected on a routine follow-up visit, and local recurrences often presented without new symptoms. Routine post-treatment follow-up of T1 glottic LSCC seems beneficial. Trial registration Trial registration number and date of registration HUS/356/2017 11.12.2017.

show abstract

“…The PubMed database search yielded a total of 260 studies (Table A1), of which 68 (26 MAs, 24 RCTs, and 18 SRs) fulfilled the selection criteria 9,13–15,29–31,33,35–94 . The countries in which the largest numbers of studies were performed were China ( n = 18), the United Kingdom ( n = 6), and Italy ( n = 5; Figure 1).…”

Section: Resultsmentioning

confidence: 99%

Overview of glottic laryngeal cancer treatment recommendation changes in the NCCN guidelines from 2011 to 2022

Arboleda,

Neves,

Kohler

et al. 2023

Cancer Reports

View full text Add to dashboard Cite

BackgroundThe treatment of glottic cancer remains challenging, especially with regard to morbidity reduction and larynx preservation rates. The National Comprehensive Cancer Network (NCCN) has published guidelines to aid decision‐making about this treatment according to the tumor site, clinical stage, and patient medical status.AimThe present review was conducted to identify changes in the NCCN guidelines for glottic cancer treatment made between 2011 and 2022 and to describe the published evidence concerning glottic cancer treatment and oncological outcomes in the same time period.Methods and ResultsClinical practice guidelines for head and neck cancer published from 2011 up to 2022 were obtained from the NCCN website (www.NCCN.org). Data on glottic cancer treatment recommendations were extracted, and descriptive analysis was performed. In addition, a review of literature registered in the PubMed database was performed to obtain data on glottic cancer management protocols and treatment outcomes from randomized controlled trials, systematic reviews, and meta‐analyses published from 2011 to 2022. In total, 24 NCCN guidelines and updates and 68 relevant studies included in the PubMed database were identified. The main guideline changes made pertained to surgical and systemic therapies, the consideration of adverse features, and new options for the treatment of metastatic disease at initial presentation. Early‐stage glottic cancer received the most research attention, with transoral endoscopic laser surgery and radiotherapy assessed and compared as the main treatment modalities. Reported associations between treatment types and survival rates for this stage of glottic cancer appear to be similar, but functional outcomes can be highly compromised.ConclusionNCCN panel members provide updated recommendations based on currently accepted treatment approaches for glottic cancer, constantly reviewing new surgical and non‐surgical techniques. The guidelines support decision‐making about glottic cancer treatment that should be individualized and prioritize patients' quality of life, functionality, and preferences.

show abstract

Efficacy of laser surgery versus radiotherapy for treatment of glottic carcinoma: a systematic review and meta-analysis

Cited by 12 publications

References 42 publications

Long‐term Oncologic Outcomes of 1188 Tis‐T2 Glottic Cancers Treated by Transoral Laser Microsurgery

Long‐term Oncologic Outcomes of 1188 Tis‐T2 Glottic Cancers Treated by Transoral Laser Microsurgery

T1 glottic laryngeal cancer: the role of routine follow-up visits in detecting local recurrence

Overview of glottic laryngeal cancer treatment recommendation changes in the NCCN guidelines from 2011 to 2022

Contact Info

Product

Resources

About